Clinical trial
Tamoxifen in Treating Women With High-Risk Breast Cancer
NCT00002542 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00002542 |
|---|---|
| Title | Tamoxifen in Treating Women With High-Risk Breast Cancer |
| Official title | Double-Blind Randomized Trial of Tamoxifen Versus Placebo in Patients With Node Positive or High Risk Node Negative Breast Cancer Who Have Completed CMF, CEF, or AC Adjuvant Chemotherapy |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug, Radiation |
| Interventions | CMF regimen, cyclophosphamide, doxorubicin hydrochloride, epirubicin hydrochloride, fluorouracil, methotrexate, tamoxifen citrate, radiation therapy |
| Enrollment | 672 |
| Start date | Jul 20, 1993 |
| Primary completion | Mar 7, 2007 |
| Completion | Jan 11, 2011 |
| First posted | Jul 29, 2004 |
| Last update posted | Apr 1, 2020 |
| Countries | Canada |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: